Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q27853062)
Watch
English
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer
scientific article
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
PubMed ID
25184630
retrieved
13 November 2016
title
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer
(English)
1 reference
stated in
PubMed
PubMed ID
25184630
retrieved
13 November 2016
main subject
prostate cancer
1 reference
based on heuristic
inferred from title
author
Tamara L Lotan
series ordinal
11
object named as
Tamara L Lotan
0 references
William B Isaacs
series ordinal
15
object named as
William B Isaacs
0 references
Angelo M De Marzo
series ordinal
13
object named as
Angelo M De Marzo
0 references
author name string
Emmanuel S Antonarakis
series ordinal
1
0 references
Changxue Lu
series ordinal
2
0 references
Hao Wang
series ordinal
3
0 references
Brandon Luber
series ordinal
4
0 references
Mary Nakazawa
series ordinal
5
0 references
Jeffrey C Roeser
series ordinal
6
0 references
Yan Chen
series ordinal
7
0 references
Tabrez A Mohammad
series ordinal
8
0 references
Yidong Chen
series ordinal
9
0 references
Helen L Fedor
series ordinal
10
0 references
Qizhi Zheng
series ordinal
12
0 references
John T Isaacs
series ordinal
14
0 references
Rosa Nadal
series ordinal
16
0 references
Channing J Paller
series ordinal
17
0 references
Samuel R Denmeade
series ordinal
18
0 references
Michael A Carducci
series ordinal
19
0 references
Mario A Eisenberger
series ordinal
20
0 references
Jun Luo
series ordinal
21
0 references
language of work or name
English
0 references
publication date
11 September 2014
0 references
published in
The New England Journal of Medicine
0 references
volume
371
0 references
page(s)
1028-38
0 references
issue
11
0 references
cites work
A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
20 March 2017
Abiraterone in metastatic prostate cancer without previous chemotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
20 March 2017
Androgen receptor variants occur frequently in castration resistant prostate cancer metastases
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
20 March 2017
Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
20 March 2017
Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
20 March 2017
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
20 March 2017
Development of a second-generation antiandrogen for treatment of advanced prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
20 March 2017
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
20 March 2017
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
20 March 2017
Overcoming mutation-based resistance to antiandrogens with rational drug design
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
20 March 2017
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
20 March 2017
Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
20 March 2017
Increased survival with enzalutamide in prostate cancer after chemotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
7 April 2017
Abiraterone and increased survival in metastatic prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
7 April 2017
Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
29 September 2017
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
29 September 2017
A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
29 September 2017
NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
29 September 2017
FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
29 September 2017
Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
29 September 2017
Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
29 September 2017
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
29 September 2017
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
29 September 2017
Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
29 September 2017
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
29 September 2017
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
29 September 2017
Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
29 September 2017
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
29 September 2017
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
29 September 2017
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
29 September 2017
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
29 September 2017
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
29 September 2017
New therapies for castration-resistant prostate cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201502
retrieved
27 November 2018
Identifiers
DOI
10.1056/NEJMOA1315815
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
765466
OpenCitations bibliographic resource ID
765466
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
765466
PMCID
4201502
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
765466
PubMed ID
25184630
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
765466
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
